< Back to all Breaking News
ARGS
4/19/2018 08:04am
Argos Therapeutics to discontinue Phase 3 ADAPT trial of Rocapuldencel-T
Don't miss out!
We read the Wall Street research, SEC filings and press releases so you don't have to.
Sign up for our 14-day free trial to read this story.